COVID–Flu Vaccine: Who Can Receive mCombriax in Europe?

What does approval of the combined COVID–flu vaccine mean?

The European Commission granted mCombriax marketing authorization on April 20, 2026. That followed a February recommendation from the European Medicines Agency's human medicines committee, which included the vaccine among 12 medicines recommended for approval. These are earlier regulatory milestones, rather than a new authorization announced on October 14. A committee recommendation and a final marketing authorization are separate steps. [EMA meeting highlights](https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-february-2026); [EMA authorization record](https://www.ema.europa.eu/en/medicines/human/EPAR/mcombriax).

The vaccine uses messenger RNA instructions to help the immune system recognize proteins associated with SARS-CoV-2 and seasonal influenza. Its influenza targets include A/H1N1, A/H3N2 and B/Victoria. Combining the components provides one injection against two respiratory infections. The practical promise is simpler vaccination, although whether this increases uptake will depend on how vaccination programs use it. [EMA vaccine explanation](https://www.ema.europa.eu/en/news/first-combined-covid-19-influenza-vaccine-people-50-years-older).

How strong is the clinical evidence for mCombriax?

The pivotal study, published in JAMA in 2025, enrolled and vaccinated 8,015 adults across 146 US sites. Participants received either the investigational combination, known as mRNA-1083, or separate licensed vaccines administered together. Adults aged 65 and older received a high-dose influenza vaccine in the comparison group; those aged 50–64 received a standard-dose influenza vaccine. Both comparison groups also received a COVID-19 vaccine. [JAMA randomized trial](https://jamanetwork.com/journals/jama/fullarticle/2833668).

The combination met the trial's noninferiority criteria for antibody responses: it performed within the predefined limits used to judge whether an immune response was acceptably comparable. Some antibody measurements were higher with the combination. However, the primary assessment concerned immune responses, not a direct comparison of hospitalizations or deaths. Higher antibody levels should therefore not be translated into an unsupported percentage reduction in severe illness. [JAMA findings and limitations](https://jamanetwork.com/journals/jama/fullarticle/2833668).

What should patients know about side effects and access?

EMA lists injection-site pain, fatigue, headache, muscle or joint pain, chills and fever among common reactions. Its assessment found that side effects occurred more often with mCombriax than with the comparison vaccine combinations, but were generally mild and short-lived. This matters when weighing the convenience of a combined injection against the possibility of temporary discomfort. Safety monitoring continues after authorization. [EMA benefit–risk assessment](https://www.ema.europa.eu/en/medicines/human/EPAR/mcombriax).

Authorization does not establish that every clinic stocks the vaccine or that every eligible adult receives it without charge. National authorities determine vaccination recommendations, and access also involves local purchasing and reimbursement decisions. Patients considering the combination should check which vaccines their vaccination service offers and how those options fit their recommended schedule. [EMA explanation of patient access](https://www.ema.europa.eu/en/news/first-combined-covid-19-influenza-vaccine-people-50-years-older).